Roche takes a look at Phylogica's peptide technology
This article was originally published in Scrip
Roche has signed an agreement to evaluate peptide technology developed by the Australian drug discovery firm Phylogica, which can potentially be applied to the transport of large molecule therapeutics to disease targets within cells. Financial details of the tie-up were not disclosed.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.